| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/14/2022 | 27.84% | JP Morgan | → $27 | Initiates Coverage On | → Overweight |
| 11/14/2022 | 18.37% | Jefferies | → $25 | Initiates Coverage On | → Buy |
| 11/14/2022 | 8.9% | Morgan Stanley | → $23 | Initiates Coverage On | → Equal-Weight |
| 11/14/2022 | 4.17% | Goldman Sachs | → $22 | Initiates Coverage On | → Neutral |
What is the target price for Prime Medicine (PRME)?
The latest price target for Prime Medicine (NASDAQ: PRME) was reported by JP Morgan on November 14, 2022. The analyst firm set a price target for $27.00 expecting PRME to rise to within 12 months (a possible 27.84% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Prime Medicine (PRME)?
The latest analyst rating for Prime Medicine (NASDAQ: PRME) was provided by JP Morgan, and Prime Medicine initiated their overweight rating.
When is the next analyst rating going to be posted or updated for Prime Medicine (PRME)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Prime Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Prime Medicine was filed on November 14, 2022 so you should expect the next rating to be made available sometime around November 14, 2023.
Is the Analyst Rating Prime Medicine (PRME) correct?
While ratings are subjective and will change, the latest Prime Medicine (PRME) rating was a initiated with a price target of $0.00 to $27.00. The current price Prime Medicine (PRME) is trading at is $21.12, which is within the analyst's predicted range.